These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 14521170)

  • 1. Computerized generation of circadian sensor modal days with continuous glucose monitoring for comparison of various insulin regimens based on insulin glargine in type 1 diabetes.
    Howorka K; Pumprla J; Gabriel M; Thoma H; Schabmann A
    Int J Artif Organs; 2003 Aug; 26(8):728-34. PubMed ID: 14521170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
    Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
    Rosenstock J; Park G; Zimmerman J;
    Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial.
    Tanenberg R; Bode B; Lane W; Levetan C; Mestman J; Harmel AP; Tobian J; Gross T; Mastrototaro J
    Mayo Clin Proc; 2004 Dec; 79(12):1521-6. PubMed ID: 15595336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison between basal insulin glargine and NPH insulin in patients with diabetes type 1 on conventional intensive insulin therapy].
    Pesić M; Zivić S; Radenković S; Velojić M; Dimić D; Antić S
    Vojnosanit Pregl; 2007 Apr; 64(4):247-52. PubMed ID: 17580534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Degludec is superior to glargine in terms of daily glycemic variability in people with type 1 diabetes mellitus.
    Yamamoto C; Miyoshi H; Fujiwara Y; Kameda R; Ichiyama M; Nomoto H; Kameda H; Nakamura A; Atsumi T
    Endocr J; 2016; 63(1):53-60. PubMed ID: 26522272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of conventional blood glucose monitoring as an indicator of integrated glucose values using a continuous subcutaneous sensor.
    Zavalkoff SR; Polychronakos C
    Diabetes Care; 2002 Sep; 25(9):1603-6. PubMed ID: 12196434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycemic exposure is affected favorably by inhaled human insulin (Exubera) as compared with subcutaneous insulin glargine (Lantus) in patients with type 2 diabetes.
    Hompesch M; Kollmeier A; Rave K; Heinemann L; Mitnick M; Davies S; Strack T
    Diabetes Technol Ther; 2009 May; 11(5):307-13. PubMed ID: 19537357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
    Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
    Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study.
    Ludvigsson J; Hanas R
    Pediatrics; 2003 May; 111(5 Pt 1):933-8. PubMed ID: 12728068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous glucose monitoring and the reality of metabolic control in preschool children with type 1 diabetes.
    Jeha GS; Karaviti LP; Anderson B; Smith EO; Donaldson S; McGirk TS; Haymond MW
    Diabetes Care; 2004 Dec; 27(12):2881-6. PubMed ID: 15562201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of moderate-severe exercise on blood glucose in Type 1 diabetic adolescents treated with insulin pump or glargine insulin.
    Delvecchio M; Zecchino C; Salzano G; Faienza MF; Cavallo L; De Luca F; Lombardo F
    J Endocrinol Invest; 2009 Jun; 32(6):519-24. PubMed ID: 19474521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes.
    Kudva YC; Basu A; Jenkins GD; Pons GM; Quandt LL; Gebel JA; Vogelsang DA; Smith SA; Rizza RA; Isley WL
    Diabetes Care; 2005 Jan; 28(1):10-4. PubMed ID: 15616226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical performance of CGMS in type 1 diabetic patients treated by continuous subcutaneous insulin infusion using insulin analogs.
    Guerci B; Floriot M; Böhme P; Durain D; Benichou M; Jellimann S; Drouin P
    Diabetes Care; 2003 Mar; 26(3):582-9. PubMed ID: 12610005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.
    Ahmed AB; Mallias J; Home PD
    Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of the continuous glucose monitoring system in Goettingen Minipigs, with a special focus on the evaluation of insulin-dependent diabetes.
    Strauss A; Tiurbe C; Chodnevskaja I; Thiede A; Timm S; Ulrichs K; Moskalenko V
    Transplant Proc; 2008 Mar; 40(2):536-9. PubMed ID: 18374123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.
    Torres I; Ortego J; Valencia I; García-Palacios MV; Aguilar-Diosdado M
    Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):378-85. PubMed ID: 19629931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basal-bolus insulin therapy in Type 1 diabetes: comparative study of pre-meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin.
    Herz M; Arora V; Sun B; Ferguson SC; Bolli GB; Frier BM
    Diabet Med; 2002 Nov; 19(11):917-23. PubMed ID: 12421428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart.
    Ashwell SG; Gebbie J; Home PD
    Diabet Med; 2006 Aug; 23(8):879-86. PubMed ID: 16911626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.